Clinical benefits of single vs repeated courses of mesenchymal stem cell therapy in epilepsy patients.

Clinical Neurology and Neurosurgery
Fedor HlebokazovNatalia Goncharova

Abstract

Epilepsy is defined as "drug-resistant" when existing anti-epileptic drugs (AED) are found to have minimal to no effect on patient's condition. Therefore the search and testing of new treatment strategies is warranted. This study focuses on the effects of autologous mesenchymal stem cells (MSC) in drug-resistant epilepsy patients within a Phase I/II open-label registered clinical trial NCT02497443. A total of 67 patients was included (29 males, 38 females, mean age 33 ± 1.3 yo). The patients received either standard treatment with AEDs, or AEDs supplemented with one or two courses of therapy with autologous bone marrow-derived MSCs expanded in vitro. MSC therapy courses were 6 months apart, and each course consisted of two cell injections: an intravenous infusion of MSCs, followed within 1 week by an intrathecal injection. Primary outcome of the study was safety, secondary outcome was efficacy in terms of seizure frequency reduction and response to treatment. MSC injections proved safe and did not cause any severe side effects. In MSC group (n = 34), 61.7% patients responded to therapy at 6 months timepoint (p < 0.01 vs control, n = 33), and the number rose to 76.5% by 12 months timepoint. Decrease in anxiety and depression sco...Continue Reading

References

Jun 1, 1983·Acta Psychiatrica Scandinavica·A S Zigmond, R P Snaith
Aug 30, 2005·European Journal of Pharmacology·Nathalie LambengPierre Chatelain
Dec 1, 2005·Brain : a Journal of Neurology·Stefan Remy, Heinz Beck
Dec 7, 2005·Proceedings of the National Academy of Sciences of the United States of America·James R MunozDarwin J Prockop
Jul 1, 2008·Therapeutic Advances in Neurological Disorders·Rainer SurgesMatthew C Walker
Mar 24, 2012·Bulletin of Experimental Biology and Medicine·A V ShakhbazauM P Potapnev
May 4, 2013·Seizure : the Journal of the British Epilepsy Association·Gang LiHajo M Hamer
Mar 7, 2017·Neuropsychiatric Disease and Treatment·Gautam RaoCesar V Borlongan
Apr 4, 2017·British Journal of Clinical Pharmacology·Gaetano ZaccaraFrancesco Mandò Tacconi
Jun 25, 2017·Scientific Reports·Luís F MartinsRamiro D Almeida
Jun 20, 2019·Frontiers in Immunology·Andreas Robert Rudolf Weiss, Marc Hendrik Dahlke
Jul 3, 2019·Nature Reviews. Neurology·Annamaria VezzaniTeresa Ravizza
Aug 8, 2019·Stem Cell Research & Therapy·Anwen ShaoJianmin Zhang
Sep 20, 2019·Neural Regeneration Research·Fábio G Teixeira, António J Salgado
Oct 23, 2019·Epilepsy & Behavior : E&B·Dinesh Upadhya, Ashok K Shetty
Dec 19, 2020·Clinical Neurology and Neurosurgery·Hadi AligholiAli A Asadi-Pooya

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.